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Background: Many patients with glaucoma have difﬁculty using antiglaucoma eye drops because of dry
eye symptom. In this prospective, randomized, double-blind, placebo-controlled study, we evaluated the
effect of Korean Red Ginseng on dry eye syndrome in patients with glaucoma treated with antiglaucoma
eye drops.
Methods: Forty-nine participants were allocated to the Korean Red Ginseng (3 g/day; n ¼ 24) or placebo
(n ¼ 25) groups for 8 weeks. Tear ﬁlm stability, ﬂuorescein corneal staining, conjunctival hyperemia, tear
production, grade of meibomian gland dysfunction, and dry eye questionnaire (Ocular Surface Disease
Index) were evaluated at baseline and on completion of the treatment.
Results: Almost all patients displayed dry eye symptoms and signs at baseline. After the 8-week inter-
vention, Korean Red Ginseng supplementation signiﬁcantly improved the tear ﬁlm stability and total
Ocular Surface Disease Index score, as compared to placebo (p < 0.01).
Conclusion: Korean Red Ginseng supplementation may provide an additional treatment option for dry
eye and patients with glaucoma using antiglaucoma eye drops.
Copyright  2014, The Korean Society of Ginseng, Published by Elsevier. All rights reserved.1. Introduction
Glaucoma is a chronic and progressive optic neuropathy char-
acterized by visual ﬁeld loss and is the second leading cause of
global blindness after cataract [1]. The primary goal of glaucoma
treatment is to reduce intraocular pressure (IOP) using anti-
glaucoma eye drops, laser treatment, or surgery [2,3]. Anti-
glaucoma eye-drop application is the most common therapy, and
can signiﬁcantly lower IOP and delay glaucoma progression [4,5].
However, patients with glaucoma who use antiglaucoma eye drops
have been shown to have a higher prevalence of ocular surface
disease than the normal population [6,7]. Irritation and conjunc-
tival hyperemia induced by dry eyes are among the main problemsology, Severance Hospital, Institut
erms of the Creative Commons At
ribution, and reproduction in any
e Korean Society of Ginseng, Publwhen treating patients with glaucoma who require a lifetime
management [8e10]. Dry-eye therapy has been solely symptom-
atic, mainly by the application of artiﬁcial tears. However,
numerous recent studies have demonstrated that inﬂammation
and apoptosis may play key roles in the development of dry eye
syndrome (DES) [11e16].
Ginseng (the root of Panax ginseng Meyer) is a valuable folk
medicine used in East Asian countries. The two kinds of ginseng,
air-dried white ginseng and steamed red ginseng, harbor a variety
of active components, including ginsenosides, polysaccharides,
peptides, polyacetylenic alcohols, and fatty acids, and its diverse
pharmacological effects have been observed in the central nervous
system and the cardiovascular, endocrine, and immune systemse of Vision Research, Yonsei University College of Medicine, 134 Shinchon-dong,
tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)
medium, provided the original work is properly cited.
ished by Elsevier. All rights reserved.
J Ginseng Res 2015;39:7e138[17e25]. Korean Red Ginseng (KRG) is known to have more phar-
macological effects than raw ginseng because of the change of its
chemical components (such as Rg3 and Rh2) that are produced in
the steaming process [26].
Because of chronic inﬂammation, conjunctival pathological
changes, including squamous metaplasia and goblet cell loss, have
been found on cytological analysis of dry eye disease and, thus,
anti-inﬂammatory drugs, such as topical steroid and cyclosporine
A, are effective agents for DES [27,28]. In an earlier study performed
by the authors [29], participants stated that the discomfort caused
by antiglaucoma eye drops was relieved by KRG intake. Further-
more, the symptoms and signs of dry eyes were improved in some
of these patients.
In this randomized, double-blind, placebo-controlled study, we
examined the effect of KRG supplementation on DES in patients
with glaucoma.
2. Materials and methods
2.1. Ethical statement
This prospective, randomized, double-blind, placebo-controlled,
parallel group study was performed at the glaucoma clinic of the
Severance Hospital, Seoul, Korea. The study was conducted in
accordance with the Declaration of Helsinki, and informed written
consent was obtained from each participant. The Institutional Re-
view Board of the Yonsei University Health System approved the
study protocol.
2.2. Participants
Participants were enrolled prospectively between July 2013 and
December 2013. Inclusion criteria were an age of 20e75 years,
diagnosis of glaucoma, established topical hypotensive therapy
using only travoprost, and presence of subjective dry eye symp-
toms, including a tear ﬁlm breakup time (TBUT) < 10 seconds and a
Schirmer I test < 15 mm in at least one eye. One eye of each patient
was selected randomly when both eyes were eligible. Glaucoma-
tous eyes were deﬁned by a glaucoma specialist based on a glau-
comatous visual ﬁeld (VF) defect conﬁrmed by two reliable VF tests
and typical appearance of a glaucomatous optic nerve head
including cup-to-disc ratio > 0.7, intereye cup asymmetry > 0.2, or
neuroretinal rim notching, focal thinning, disc hemorrhage, or
vertical elongation of the optic cup. Exclusion criteria included a
history of any ocular surgery, evidence of acute or chronic in-
fections, an inﬂammatory condition of the eye, a history of intol-
erance or hypersensitivity to any component of the study
medications, women of childbearing age, and the presence of cur-
rent punctal occlusion. Patients with media opacity or other dis-
eases affecting the VF were also excluded. All participants were
provided with the same artiﬁcial tears (1 mg sodium hyaluronate)
to use as required during the study period, whereas individuals
whowere onmedications for dry eye treatment other than artiﬁcial
tears were excluded.
2.3. Study design
Participants were randomized to receive one of two treatment
regimens for 8weeks. The treatments were 1 g of KRG administered
as two 500-mg powder capsules or placebo administered as two
identically appearing capsules, taken three times daily in both
groups. KRG powder was manufactured by the Korea Ginseng
Corporation (Seoul, Republic of Korea) from roots of a 6-year-old
KRG, Panax ginseng, harvested in the Republic of Korea. KRG was
made by steaming fresh ginseng at 90e100C for 3 hours and thendrying at 50e80C. KRG powder prepared from grinded red
ginseng, and a capsule contained 500 mg of powder. KRG was
analyzed by high-performance liquid chromatography. KRG extract
contained major ginsenoside-Rb1: 5.61 mg/g, -Rb2: 2.03 mg/g, -Rc:
2.20 mg/g, -Rd: 0.39 mg/g, -Re: 1.88 mg/g, -Rf: 0.89 mg/g, -Rg1:
3.06 mg/g, -Rg2s: 0.15 mg/g, -Rg3s: 0.17 mg/g, -Rg3r: 0.08 mg/g,
and other minor ginsenosides. Placebo capsules were also provided
by the Korea Ginseng Corporation, and they were identical in size,
weight, color, and taste. The participants were instructed to avoid
taking other forms of KRG or any type of ginseng for the duration of
the study.
Group assignment of the participants was determined prior to
the initiation of the study. Block randomization, which was
generated by our institutional biostatistics department using a
computer-generated random sequence, was used to randomize the
participants. Study investigators, participants, and their caregivers
were blinded through the provision of themedication as identically
appearing capsules in boxes, with neither the investigator
providing the medication nor the participants aware of the allo-
cated treatment.
We performed objective clinical measurements of all partici-
pants, including tear ﬁlm stability (TBUT), ocular surface health
(ﬂuorescein ocular surface staining), conjunctival hyperemia, tear
production (Schirmer I test), and the grade of meibomian gland
dysfunction (MGD), at baseline and again 8 weeks after the daily
oral administration of 3 g of KRG or placebo. Subjective assessment
of DES using a questionnaire was also conducted at each visit.
2.4. Outcome measures
The TBUT was identiﬁed following the procedure reported by
Lemp [30]. A ﬂuorescein strip (Haag-Streit AG, Köniz, Switzerland)
was moistened with a drop of saline solution, and placed on
the inferior palpebral conjunctiva. The patients were asked to
blink several times to mix the ﬂuorescein with the tear ﬁlm. They
were instructed to open their eyes and not blink, and the time
between eye opening and the appearance of the ﬁrst dry spot
wasmeasured in seconds. This procedurewas repeated three times,
and the mean of the three measurements was recorded ﬁnally as
TBUT.
After the measurement of the TBUT, ﬂuorescein staining on the
ocular surface was evaluated using the standardized methods
recommended by the National Institutes of Health Symposium on
Dry Eye [30]. Brieﬂy, corneal staining was scored 3 minutes after
ﬂuorescein instillation by observing the cornea through a cobalt
blue light. It was graded using a scale of 0e3 (absent to diffuse) and
recorded for the ﬁve corneal sections (central, superior, temporal,
nasal, and inferior.). The maximum score for each area was 3. The
scores of the ﬁve areas were summed to obtain a total score for each
eye, producing a maximum score of 15.
Conjunctival hyperemiawas evaluated by the investigator based
on a visual inspection. A standard ﬁve-point scoring system was
used with the following descriptors based on photographic stan-
dards: 0 (none) ¼ normal, bulbar conjunctival vessels easily
observed; þ0.5 (trace) ¼ trace ﬂush, reddish-pink color; þ1
(mild) ¼ mild ﬂush, reddish color; þ2 (moderate) ¼ bright red
color; and þ3 (severe) ¼ deep, bright, diffuse redness.
The Schirmer I test was performed under anesthesia. To obtain
anesthetic conditions of all the ocular structures, more than three
drops of topical anesthetic (proparacaine hydrochloride
ophthalmic solution 0.5%) were applied to the conjunctiva and both
lid margins. Then, Schirmer strip was placed on the lower lid 2 mm
lateral to the lateral canthus. Patients sat in the dark with both eyes
closed for 5 minutes. After the strip was removed, a length of the
wet area of the strip was measured in millimeters.
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evaluated using manual expression. The quantity was graded using
a three-point scale: 0 ¼ normal; 1 ¼ delay; 2 ¼ partially blocked;
and 3 ¼ blocked. The quality was also scored similarly: 0 ¼ clear;
1 ¼ cloudy; 2 ¼ granular; and 3 ¼ opaque solid.
To evaluate subjective symptoms of dry eye, the participants
were asked to complete the Ocular Surface Disease Index (OSDI)
prior to taking any clinical measurements. The OSDI is a disease-
speciﬁc questionnaire used to quantify the speciﬁc effect of DES on
vision-related quality of life [31]. It includes three subscales: ocular
discomfort (OSDI-symptom); vision-related function (OSDI-func-
tion); and environmental triggers (OSDI-trigger). The patients
answered the 12 items on the OSDI questionnaire that were graded
on a scale of 0e4 (0: none of the time, 1: some of the time, 2: 50% of
the time, 3: most of the time, and 4: all of the time). The OSDI score
was calculated from (sum of the scores for all the questions
answered)  25/(the total number of the questions answered).
Scores range over 0e100 for the overall score and in each category.
A score of 0e12 indicates a normal eye, 13e22 a mild dry eye, 23e
32 amoderate dry eye, and> 33 a severe dry eye. It should be noted
that a decrease in the OSDI score indicates an improvement.
2.5. Statistical analysis
The basic characteristics were compared between the two
groups using an independent t test for continuous variables or the
Chi-square test for categorical variables. The comparisons of
outcome measures between the baseline and 8-week visits in each
group were performed using a paired t test and the differences in
the degree of change were compared between the two groups us-
ing an independent t test. Statistical analysis was performed using
SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). A value of p < 0.05
was considered signiﬁcant.
3. Results
A total of 54 participants were included in this study and were
randomly assigned to two groups prior to the study initiation, the
KRG and placebo groups, of whom 49 participants (24 participants
and 25 participants in the KRG and placebo groups, respectively)
successfully completed the study (Fig. 1). No signiﬁcant side effect
related to the KRG or placebo was found. The two groups were
comparable in their basic characteristics: the mean ages were 59.5
years and 62.0 years (KRG and placebo, respectively); there were
slightly more women than men in both groups; and mean IOP was
w12 mmHg in both groups (Table 1).Fig. 1. Participants’ enr3.1. Clinical assessment
Compared to the baseline, there was no statistically signiﬁcant
change after 8 weeks in the placebo group using a paired t test,
whereas in the KRG group the mean TBUT score (range from
4.21 1.53 to 6.63  1.64, p < 0.01), conjunctival hyperemia (range
from 1.02  0.60 to 0.63  0.45, p ¼ 0.01), and MGD quantity grade
(range from 1.58 0.97 to 1.04 0.55, p¼ 0.04) showed signiﬁcant
improvement. Of these, the change in the TBUT was signiﬁcantly
greater in the KRG group than in the placebo group when the dif-
ference in the degree of change between the two groups was
analyzed using an independent t test (p < 0.01) (Table 2, Fig. 2).
3.2. Subjective symptoms
Table 3 presents the results of the OSDI scores at the baseline
and 8-week visits. The mean baseline total OSDI score was
36.22  17.90 and 36.56  19.58 in the KRG and placebo groups,
respectively. Virtually all the participants had abnormal OSDI
scores. After the 8-week intervention, the total OSDI score in the
KRG group was signiﬁcantly improved from 36.22  17.90 to
27.77  21.68 (p ¼ 0.01), and it differed signiﬁcantly from the
placebo group (p ¼ 0.04). In the KRG group, the OSDI-symptom
subtotal improved the most, from 35.42  16.42 to 23.40  18.65
(p < 0.01), which was thought to affect the greater part of the total
OSDI score improvement. Compared to the baseline, six of the 12
items were signiﬁcantly improved in the KRG group after the 8-
week supplementation: three items (painful eye, blurred vision,
and poor vision) of the OSDI-symptom; two items of OSDI-function
(driving at night and working with a computer); and one item
(feeling uncomfortable in air-conditioned areas). In addition, ﬁve of
these items, except blurred vision, displayed signiﬁcant differences
between the KRG and placebo groups.
4. Discussion
Patients with full-blown glaucoma suffer from the disease itself.
However, most patients, particularly those in the early to moderate
stages of glaucoma, complain more about their dry eye symptoms
caused by topical glaucoma medication until the disease pro-
gressed. Many earlier studies reported that patients with glaucoma
suffer a higher prevalence of ocular surface disease than the normal
population [7e10]. Leung et al [10] found that 59% of patients with
primary open-angle glaucoma (OAG) and ocular hypertension
(OHT) reported dry eye symptoms, whereas severe symptoms were
noted by 27% of these patients. The authors concluded that a largeollment ﬂowchart.
Table 1
Baseline characteristics of the study participants
KRG group Placebo group p1)
No. 24 25
Mean age, y  SD 59.5  10.5 62.0  9.4 0.38
Female sex 13 (54) 16 (64) 0.48
Mean BCVA, Snellen  SD 0.9  0.2 0.9  0.1 0.68
Mean IOP, mmHg  SD 12.9  2.8 12.2  2.3 0.36
Diagnosis
Open-angle glaucoma 21 (88) 21 (84) 0.52
Angle-closure glaucoma 1 (4) 3 (12)
Secondary glaucoma 2 (8) 1 (4)
Data are presented as n (%), unless otherwise indicated
BCVA, best corrected visual acuity; IOP, intraocular pressure; KRG, Korean Red
Ginseng; SD, standard deviation
1) p values were derived from an independent t test for continuous data and the
Chi-square test for categorical data
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symptoms of dry eye, and that the presence of dry eye and the use
of benzalkonium chloride (BAK)-containing medications may affect
quality of life. Our study similarly demonstrated that dry eye is
prevalent in patients treated for glaucoma by showing that almost
all the participants had OSDI scores consistent with the presence of
dry eye symptoms.
The cause of DES in patients with glaucoma is thought to be
multifactorial and may include an active ingredient and a preser-
vative, most commonly BAK [9,32]. Several previous studies re-
ported that BAK may cause inﬂammation and potentially other
ocular diseases, including allergy, blepharitis, DES, and anatomical
eyelid abnormalities [33,34]. The prolonged use of preserved
topical drugs is an extrinsic cause of increased tear evaporation,
which induces a toxic response from the ocular surface. BAK has a
well-known dose-dependent toxicity and is most commonly used
as a preservative in ophthalmic solutions, particularly in anti-
glaucoma eye drops [33,35]. Its cellular toxicity has been demon-
strated experimentally in in vitro studies of conjunctiva-derived
and corneal cells [36,37]. BAK induces the expression of inﬂam-
matory cell markers at the ocular surface [38] and causes epithelial
cell damage, apoptotic cell death, and a decrease in goblet cell
density, resulting in tear ﬁlm instability and tear hyperosmolarity
[39,40].
In recent years, the immune system has been thought to play an
increasingly important role in the pathogenesis of dry eye. Studies
have demonstrated an inﬁltration of the conjunctival epithelia with
inﬂammatory cells, particularly lymphocytes [41e43]. Further-
more, changes in the expression of immune system stimulation
markers, including the intracellular adhesion molecule I antigenTable 2
Comparison of the clinical assessment for dry eye
KRG group (n ¼ 24)
Baseline 8-wk visit p1)
Corneal staining (0e15) 1.63  1.41 1.40  1.41 0
TBUT (s) 4.21  1.53 6.63  1.64 < 0
Schirmer I test (mm) 5.00  4.45 5.46  4.46 0
Conjunctival hyperemia (0e3) 1.02  0.60 0.63  0.45 0
MGD, quality (0e3) 1.38  0.65 1.17  0.56 0
MGD, quantity (0e3) 1.58  0.97 1.04  0.55 0
Data are expressed as mean  standard deviation, unless otherwise indicated
*p < 0.05
**p < 0.01
KRG, Korean Red Ginseng; MGD, meibomian gland dysfunction; TBUT, tear breakup tim
1) p values were derived from a paired t test between the baseline and 8-wk visits in e
2) p values were derived from an independent t test between changes in the KRG andand the human leukocyte antigen D receptor (HLA-DR), which
induce T-cell homing and antigen presentation, were observed in
the context of dry eye [44]. Several studies reported alterations in
the protein expression proﬁles of cytokines in the tears of patients
with DES. This suggests that dry eye is the result of inﬂammatory
reactions, which are caused by cytokines, resulting in an autoim-
mune response [45]. Moreover, recent studies have shown the
positive effect of oral omega-3 and -6 essential fatty acid supple-
mentation in DES with an inﬂammatory component [46e48].
Reduced dry eye symptoms were reported as well as an improve-
ment in objective signs, including corneal staining and decreased
conjunctival HLA-DR expression. Oral omega-6 supplementation
also increased tear production and reduce dry eye symptoms after
photorefractive keratectomy [49].
Ginsenosides, unique saponins contained in the Panax species,
are believed to be responsible for most of the pharmacological
actions of ginseng, which include anti-inﬂammatory, -stress, and
-oxidant activities [50e53]. Many studies have reported the anti-
inﬂammatory effects of ginseng extracts and ginsenosides on
cellular responses triggered by various inducers, including endo-
toxin, tumor necrosis factor-a, and interferon-g [54e56]. Ginseng
extracts and ginsenosides, including Rb1, Rb2, Rc, Rd, Re, Rf, Rg1,
and Rg2 have been reported to have anti-inﬂammatory properties
in different forms of inﬂammation [57]. Ginsenosides inhibit
various inducer-activated signaling protein kinases and nuclear
factor kappa-light-chain-enhancer of activated B cells transcription
factor, resulting in decreased production of cytokines and inﬂam-
mation mediators [58,59]. Based on these studies, we hypothesized
that the anti-inﬂammatory property of KRG may have a positive
effect on the ocular surface. This KRG anti-inﬂammatory effect
improved tear ﬁlm instability, and consequently the TBUT was
increased. Additionally, there were signiﬁcant improvements in
conjunctival hyperemia and MGD quantity after KRG supplemen-
tation, although these were not signiﬁcantly different from the
placebo group. These results strongly support our hypothesis
regarding the anti-inﬂammatory effects of KRG on dry eye. This
hypothesis should be conﬁrmed by additional in vitro and in vivo
studies.
In the current study, we also found an improvement in subjec-
tive dry eye symptoms determined using the OSDI questionnaire in
the KRG group, as compared to the placebo group. Because the
TBUT was signiﬁcantly improved after 8 weeks in the KRG group,
we can presume that this ﬁnding may be associated with the
improvement in the total OSDI score, including the subtotal OSDI-
symptom score. The improvement in tear ﬁlm stability was thought
to play an important role in making the patients feel more
comfortable. This is consistent with previous studies, which re-
ported that the TBUT is related to the dry eye symptoms [60,61].Placebo group (n ¼ 25) p2)
Baseline 8-wk visit p1)
.35 1.64  1.60 1.92  2.18 0.28 0.16
.01** 3.84  1.60 4.24  1.33 0.41 < 0.01**
.35 7.56  4.24 6.88  6.65 0.53 0.34
.01* 0.84  0.50 0.76  0.58 0.43 0.06
.14 1.56  0.51 1.48  0.59 0.57 0.51
.04* 1.80  0.87 1.64  0.70 0.33 0.20
e
ach group
placebo groups
Fig. 2. Changes in the clinical assessment for dry eye before and after the intervention. *p< 0.05 by a paired t test in the KRG and placebo groups. **p < 0.05 by an independent t test
between changes in the KRG and placebo groups. KRG, Korean Red Ginseng; MGD, meibomian gland dysfunction; TBUT, tear breakup time.
H.W. Bae et al / Effect of KRG on dry eye in glaucoma 11This study has several limitations. First, its limited duration did
not allow us to predict how long the effects of KRG administration
would persist. The duration of the effect and optimal administra-
tion schedule for KRG treatment requires further investigation in
patients with glaucoma. Second, because this study was performed
only with Korean participants, we could not exclude any possible
ethnic-related differences. Third, we did not evaluate the systemic
effects of KRG, although no adverse events were noted during theTable 3
Changes in subjective dry eye symptoms using the OSDI score
KRG group (n
Baseline 8-wk vis
Light-sensitive eyes (0e4) 1.27  1.20 0.95 
Gritty eyes (0e4) 1.23  0.81 1.00 
Painful or sore eyes (0e4) 1.90  1.07 1.00 
Blurred vision (0e4) 1.05  1.00 0.52 
Poor vision (0e4) 1.55  0.74 0.82 
OSDI symptom subtotal (0e100) 35.42  16.42 23.40 
Difﬁculty in
Reading (0e4) 1.68  1.17 1.46 
Driving at night (0e4) 1.94  1.34 1.06 
Working with a computer or a bank machine (0e4) 1.50  1.15 0.95 
Watching TV (0e4) 1.32  1.32 1.04 
OSDI vision-related function subtotal (0e100) 34.55  30.06 30.73 
Feel uncomfortable in
Windy conditions (0e4) 1.09  0.97 0.86 
Places with low humidity (0e4) 1.41  1.01 1.21 
Air-conditioned areas (0e4) 1.54  1.22 1.32 
OSDI trigger subtotal (0e100) 34.72  22.74 30.90 
Total OSDI (0e100) 36.22  17.90 27.77 
Data are expressed as mean  standard deviation
*p < 0.05
**p < 0.01
KRG ¼ Korean Red Ginseng; OSDI ¼ ocular surface disease index
1) p values were derived from a paired t-test between the baseline and 8-week visits i
2) p values were derived from an independent t-test between changes in the KRG andstudy period. Checking vital signs, including systemic blood pres-
sure, or performing blood tests to evaluate the inﬂammatory state
would have enhanced our study. Despite these limitations, this is
the ﬁrst placebo-controlled study reporting the effect of KRG sup-
plementation on the ocular surface and dry eye symptoms.
In conclusion, our results indicated that daily supplementation
of 3 g of KRG for 8 weeks signiﬁcantly improved the TBUT score and
subjective dry eye symptoms, as compared to placebo. This¼ 24) Placebo group (n ¼ 25) p2)
it p1) Baseline 8-wk visit p1)
1.40 0.19 1.26  1.21 1.09  0.90 0.76 0.40
0.74 0.21 1.14  0.99 1.21  0.98 0.06 0.04*
0.69 < 0.01** 1.74  1.56 1.29  1.46 0.33 < 0.01**
0.99 0.01* 1.55  1.43 1.73  1.58 0.84 0.12
0.85 < 0.01** 1.22  1.17 1.67  1.58 0.05 < 0.01**
18.65 < 0.01** 32.80  19.36 34.70  22.13 0.43 < 0.01**
1.10 0.16 1.56  1.36 1.54  1.53 0.65 0.24
1.06 0.01* 1.69  1.80 1.69  1.70 0.34 0.05
0.94 0.01* 1.56  1.50 1.67  1.32 0.46 0.03*
1.16 0.48 1.39  1.53 1.00  1.27 0.44 0.83
25.97 0.28 35.17  27.91 36.17  32.10 0.80 0.36
0.83 0.55 1.76  1.54 1.25  1.22 0.14 0.48
1.06 0.43 1.60  1.22 1.26  1.29 0.01* 0.43
1.04 0.04* 1.26  1.25 1.45  1.28 0.33 0.03*
23.11 0.39 38.67  30.96 34.33  27.75 0.13 0.92
21.68 0.01* 36.56  19.58 35.89  22.05 0.67 0.04*
n each group
placebo groups
J Ginseng Res 2015;39:7e1312improvement in dry eye was presumed to be induced by the anti-
inﬂammatory property of KRG. Although further studies are
required to identify a detailed mechanism, the use of KRG as a
nutritional supplement is expected to be a clinically valuable
additional option for dry eye and patients with glaucoma using
antiglaucoma eye drops.Conﬂicts of interest
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